Latest Breaking News On - Treatment related adverse events - Page 1 : comparemela.com

Clinical Presentations of Patients With Cholangiocarcinoma

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

Best practicesManaging treatmentTreatment related adverse eventsPatients withClinical presentationCholangiocarcinoma clinical presentationCholangiocarcinoma treatmentBile duct cancerBiliary tract cancerIntrahepatic cholangiocarcinomaExtrahepatic cholangiocarcinomaBile duct cancer treatment

The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

Best practicesManaging treatmentTreatment related adverse eventsBiomarker testingDiagnosing cholangiocarcinomaCholangiocarcinoma biomarker testingCholangiocarcinoma diagnosisBile duct cancerBiliary tract cancerIntrahepatic cholangiocarcinomaExtrahepatic cholangiocarcinoma

Risk Factors Leading to Various Liver Cancers

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

Best practicesManaging treatmentTreatment related adverse eventsFactors leadingVarious liverBile duct cancerBiliary tract cancerIntrahepatic cholangiocarcinomaExtrahepatic cholangiocarcinomaKlatskin tumorLiver cancerLiver cancersRisk factors

MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U S with Outstanding Safety Results

MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U S with Outstanding Safety Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGuoying zhouTreatment emergent adverse eventsTreatment related adverse eventsSerious adverse events

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled. | May 10, 2023

United statesSacituzumab govitecanSacituzumab govitecan hziyRaj malikInvestor relations corporate communicationsEuropean society for medical oncologyResearch triangle parkExchange commissionTherapeutics incAmerican cancer societyTarget effectTrilaciclib reduces ratesMultiple adverse events associatedIncluding neutropeniaEnrolled patients received priorInitial objective response rate